STN-STRUCTURE SEARCH
10/8/04

=> d ibib abs hitstr 1-96

L4 ANSWER 1 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:780372 CAPLUS
TITLE: Non-steroidal anti-inflammatory drug dosing regimen
INVENTOR(S): Gelotte, Cathy K.; Hough, Douglas R.; McNally, Gerard P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004186180	A1	20040923	US 2003-393755	20030321
PRIORITY APPLN. INFO.:			US 2003-393755	20030321

AB A method of administering non-steroidal-anti-inflammatory drugs, in particular propionic acid derivs. such as ibuprofen, or acetaminophen is provided. This method provides improved therapeutic effect, in particular pain relief, over extended time periods.

IT **55843-86-2**, Miroprofen
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory drug dosing regimen)
RN 55843-86-2 CAPLUS
CN Benzeneacetic acid, 4-imidazo[1,2-a]pyridin-2-yl-α-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:696342 CAPLUS
DOCUMENT NUMBER: 141:225302
TITLE: Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072025	A2	20040826	WO 2004-EP1342	20040213

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,

KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: DE 2002-10237423 A 20020816

AB The invention discloses a method for treatment of immunol. diseases or pathol. conditions which contain an immunol. component, using certain LCK inhibitors, which already are known as kinase inhibitors for therapy in oncol., optionally in combination with one or more other medications selected from NSAIDs, steroids, DMARDs, immunosuppressants, biol. response modifiers, and antiinfectives. Also disclosed are pharmaceutical compns. which contain the LCK inhibitors as well as the other medications, and use of LCK inhibitors for production of a pharmaceutical composition for treatment of immunol. diseases or pathol. conditions which contain an immunol. component.

IT **55843-86-2**, Miroprofen
RL: PAC (Pharmacological activity); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(LCK inhibitors for treatment of immunol. diseases, and use with other agents)

RN 55843-86-2 CAPLUS

CN Benzeneacetic acid, 4-imidazo[1,2-a]pyridin-2-yl-α-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:101449 CAPLUS

DOCUMENT NUMBER: 140:128417

TITLE: A process for the synthesis of novel 2-substituted imidazo[1,2-a]pyridines

INVENTOR(S): Raj, Kanwal; Vishnoi, Surendra Pal; Shoeb, Aboo; Gupta, Deoki Nandan; Keshri, Govind; Kamboj, Ved Prakash

PATENT ASSIGNEE(S): Council of Scientific and Industrial Research, India

SOURCE: Indian, 8 pp.
CODEN: INXXAP

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 179790	A	19971206	IN 1992-DE104	19920210

PRIORITY APPLN. INFO.: IN 1992-DE104 19920210

OTHER SOURCE(S): CASREACT 140:128417; MARPAT 140:128417

GI



I



II

AB The title compds. [I; R1 = alkoxy such as 3-ethoxy, dialkylaminoethoxy such as diethylaminoethoxy, cyclic aminoethoxy such as pyrrolidinoethoxy], useful as antiimplantation/abortifacient agents, were prepared by reacting the phenolic compound II with alkyl halides in presence of organic solvent like acetone and K2CO3 at reflux temperature Thus, refluxing 2-(4'-hydroxyphenyl)imidazo[1,2-a]pyridine with N-(2-chloroethyl)pyrrolidine.HCl in the presence of K2CO3 in Me2CO afforded 50% I [R1 = 4-(2-pyrrolidinoethoxy)]. The compds. I showed 30-100% protection against pregnancy at 2.5-20 mg/kg by oral and s.c. routes when tested in hamsters.

IT **651042-78-3P 651042-79-4P 651042-80-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(a process for the synthesis of novel 2-substituted imidazo[1,2-a]pyridines as antifertility agents)

RN 651042-78-3 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 651042-79-4 CAPLUS
CN Ethanamine, 2-(4-imidazo[1,2-a]pyridin-2-ylphenoxy)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 651042-80-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(3-ethoxyphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L4 ANSWER 16 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:14078 CAPLUS
DOCUMENT NUMBER: 140:59640
TITLE: A process for the preparation of 2-substituted and 2,5,7-tri-substituted imidazo(1,2a)pyridines via cyclocondensation reaction showing antifertility activity
INVENTOR(S): Raj, Kanwal; Vishnoi, Surendra Pal; Gupta, Deoki Nandan; Keshri, Govind; Kamboj, Ved Prakash
PATENT ASSIGNEE(S): Council of Scientific and Industrial Research, India
SOURCE: Indian, 11 pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 179788	A	19971206	IN 1992-DE102	19920210
PRIORITY APPLN. INFO.:			IN 1992-DE102	19920210

OTHER SOURCE(S): CASREACT 140:59640; MARPAT 140:59640
GI



AB A process for the preparation of novel 2-substituted and 2,5,7 trisubstituted imidazo(1,2-a)pyridines I, where R1 represents substituted phenol such as halophenyl preferably chloro or bromo Ph, Me-Ph, nitro-Ph, hydroxy-Ph, methoxy-Ph, ethoxy-Ph, carboxymethyl, carbethoxymethyl; R2= R3 = H, CH3, which comprises refluxing correspondingly substituted 2-aminopyridines of formula II where R2 and R3 represent hydrogen or Me groups with correspondingly substituted - bromoketone of the formula III where R1 represents substituted phenol such as halophenyl preferably chloro or bromophenyl, alkyl, Ph, nitro Ph, hydroxy Ph, methoxy Ph, ethoxy Ph or carboxymethyl and carbethoxymethyl; in the presence of an aprotic solvent for a period ranging from 2-24 h. at a temperature in the range 36°-90°C and recovering the 2-substituted and 2,5,7 trisubstituted imidazo(1,2-a)pyridines, of formula I by conventional methods. Thus, 2-(4-hydroxyphenyl)imidazo[1,2-a]pyridine hydrochloride was prepared as antifertility agent. The title compds. prepared by the process of the present invention found to be useful as antiimplantation abortifacient agents. These compds. when tested in hamster for antifertility activity showed 30-100% protection against pregnancy at 2.5 - 20 mg/kg by oral and s.c. routes.

IT **88467-84-9P 637768-42-4P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of substituted and substituted imidazoapyridines via cyclocondensation reaction showing antifertility activity)

RN 88467-84-9 CAPLUS

CN Phenol, 2-imidazo[1,2-a]pyridin-2-yl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 637768-42-4 CAPLUS
CN Phenol, 4-imidazo[1,2-a]pyridin-2-yl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L4 ANSWER 17 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:2623 CAPLUS
DOCUMENT NUMBER: 140:59409
TITLE: Preparation of hydroxamate derivatives of nonsteroidal antiinflammatory drugs
INVENTOR(S): Wang, Tingmin; Lai, Ching-San
PATENT ASSIGNEE(S): Medinox, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000215	A2	20031231	WO 2003-US19228	20030617
WO 2004000215	A3	20040910		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,

US 6720324 B2 20040413
PRIORITY APPLN. INFO.: US 2000-216218P P 20000705
OTHER SOURCE(S): MARPAT 138:287697
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I-IV [A = (un)substituted Ph, pyridyl, benzothiazolyl, benzoxazolyl, etc.; R1 = H, NO2, CN, (fluoro)alkyl, (cyclo)alkenyl, alkynyl, (fluoro)cycloalkyl, amino, alkoxy, acyl, carboxy, carboxamido; R2 = H, (hydroxy)alkyl, alkoxyalkyl, fluoroalkyl, cycloalkenyl, etc.; R3 = H, (fluoro)alkyl, (cyclo)alkenyl, alkynyl, (fluoro)cycloalkyl; R4 = alkyl-piperidinyl, alkyl-tetrahydropyridinyl, etc. in which the heterocycle is substituted with (hetero)aryl, thioacyl, amido, etc.; X = O, S, NR3; n = 0 - 5] were prepared For instance, (+)-V was prepared by reaction of 5-methoxycarbonyl-4-methoxymethyl-1,2,3,6-tetrahydro-2-oxo-6-(3,4-difluorophenyl)-1-[(4-nitrophenyloxy)carbonyl]pyrimidine (preparation given) and the corresponding propylamine sidechain with base (e.g., iPr2NEt) in CH2Cl2. (+)-V had antagonist potency (Kb) = 0.3 nM and Ki = 0.08 nM for the melanin-concentrating hormone receptor (mch) and Ki > 50,000 nM for two neuropeptide Y receptors and Ki > 50,000 nM three galanin receptors. I-IV are useful in the treatment of, e.g., bulimia nervosa and obesity.

IT **330963-56-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation and use of arylpyrimidines as selective melanin concentrating
hormone-1 (mch-1) receptor antagonists)

RN 330963-56-9 CAPLUS
CN 1,3-Benzenediol, 4-[[(4-imidazo[1,2-a]pyridin-2-ylphenyl)imino]methyl]-5-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:888557 CAPLUS
DOCUMENT NUMBER: 137:384841
TITLE: Preparation of imidazo[1,2-a]pyridines as mGluR5 antagonists
INVENTOR(S): Mutel, Vincent; Peters, Jens-Uwe; Wichmann, Juergen
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092086	A1	20021121	WO 2002-EP3098	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002188128	A1	20021212	US 2002-93790	20020308
US 6596731	B2	20030722		
EP 1381363	A1	20040121	EP 2002-737889	20020320
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008387	A	20040615	BR 2002-8387	20020320
JP 2004525192	T2	20040819	JP 2002-589003	20020320
US 2003212096	A1	20031113	US 2003-407928	20030404
US 2004180921	A1	20040916	US 2004-809068	20040325
PRIORITY APPLN. INFO.:			EP 2001-107562 A	20010327
			US 2002-93790 A3	20020308
			WO 2002-EP3098 W	20020320
			US 2003-407928 A3	20030404

OTHER SOURCE(S): MARPAT 137:384841

GI



I

AB The title compds. [I; R1, R2 = H, alkyl, halogen, OH, alkoxy; A = (un)substituted aryl, heteroaryl, etc.], useful for the manufacture of medicaments for the treatment or prevention of GluR5 receptor mediated disorders, such as acute and/or chronic neurol. disorders, were prepared and formulated. Thus, reacting 2-amino-4-chloropyridine with 3,4-dimethylphenacyl bromide in EtOH afforded 69% 7-chloro-2-(3,4-dimethylphenyl)imidazo[1,2-a]pyridine which showed IC50 of 0.1 μM against mGluR 5a receptor binding.

IT **885-91-6P 34658-67-8P 65964-60-5P**
88965-00-8P 100965-76-2P 158959-20-7P
205655-15-8P 326018-20-6P 419557-33-8P
420832-11-7P 475992-33-7P 475992-34-8P
475992-35-9P 475992-36-0P 475992-37-1P
475992-38-2P 475992-39-3P 475992-40-6P
475992-41-7P 475992-42-8P 475992-43-9P
475992-44-0P 475992-45-1P 475992-46-2P
475992-47-3P 475992-48-4P 475992-49-5P
475992-50-8P 475992-51-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazo[1,2-a]pyridines as mGluR5 antagonists)

RN 885-91-6 CAPLUS

CN Imidazo[1,2-a]pyridine, 7-methyl-2-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 34658-67-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 65964-60-5 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 88965-00-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 100965-76-2 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(2-benzofuranyl)- (6CI, 9CI) (CA INDEX NAME)



RN 158959-20-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 205655-15-8 CAPLUS

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 44 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:772124 CAPLUS
DOCUMENT NUMBER: 137:279190
TITLE: Preparation of imidazo[1,2-a]pyridines as NO synthase inhibitors
INVENTOR(S): Maul, Corinna; Hennies, Hagen-Heinrich; Sundermann, Bernd
PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10117183	A1	20021010	DE 2001-10117183	20010405
WO 2002080914	A2	20021017	WO 2002-EP3795	20020405
WO 2002080914	A3	20030103		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1372647	A2	20040102	EP 2002-727529	20020405
JP 2004529141	T2	20040924	JP 2002-578953	20020405
US 2004142961	A1	20040722	US 2003-678645	20031003
PRIORITY APPLN. INFO.:			DE 2001-10117183	A 20010405
			WO 2002-EP3795	W 20020405

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

OTHER SOURCE(S): MARPAT 137:279190

GI



I

AB The title compds. [I; R1, R2 = alkyl, cycloalkyl, cycloalkylalkylene, (substituted) aryl, heteroaryl, H, F, Cl, Br, I, cyano, NO2, amino, COR5, CO2H, CO2R6, OH, OR7; R3 = alkyl, cycloalkyl, cycloalkylalkylene, (substituted) aryl, heteroaryl, arylalkylene, heteroarylalkylene, CH2SR8, CH2OR8, H; R4 = H, alkyl, cycloalkyl, heterocyclyl, (substituted) aryl, heteroaryl, etc.; R5 = alkyl, cycloalkyl, cycloalkylalkylene, heterocyclyl, (substituted) aryl, heteroaryl, arylalkylene, heteroarylalkylene; R6, R7 = alkyl, cycloalkyl, cycloalkylalkylene, (substituted) aryl, heteroaryl, arylalkylene, heteroarylalkylene; R8 = alkyl, (substituted) aryl, heteroaryl, arylalkylene, heteroarylalkylene, cycloalkyl], were prepared Thus, 2-bromo-4-methoxyacetophenone was added to 2-amino-4-methylpyridine in EtOH followed by reflux for 2 h and stirring over night at room temperature to give 69% 2-(4-methoxyphenyl)-7-methylimidazo[1,2-a]pyridine. The latter at 10 μM inhibited NO synthase by 39%.

IT **65964-63-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines as NO synthase inhibitors)

RN 65964-63-8 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(4-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peroral meloxicam suspension)
RN 55843-86-2 CAPLUS
CN Benzeneacetic acid, 4-imidazo[1,2-a]pyridin-2-yl-α-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 60 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:454955 CAPLUS
DOCUMENT NUMBER: 131:110800
TITLE: Determination of non-steroidal anti-inflammatory drugs in biological fluids
AUTHOR(S): Hercegova, Andrea; Polonsky, J.
CORPORATE SOURCE: Department Analytical Chemistry, Faculty Chemical Technology, Slovak Univ. Technology, Bratislava, 81237, Slovakia
SOURCE: Pharmazie (1999), 54(7), 479-486
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 73 refs. is given on HPLC, high performance thin-layer chromatog. (HPTLC), liquid chromatog. (LC), GC/MS, capillary electrophoresis, and optical methods for the determination of non-steroidal anti-inflammatory drugs like arylpropionic acids in urine, serum, and plasma.
IT **55843-86-2**, Miroprofen
RL: ANT (Analyte); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(determination of non-steroidal anti-inflammatory drugs in biol. fluids)
RN 55843-86-2 CAPLUS
CN Benzeneacetic acid, 4-imidazo[1,2-a]pyridin-2-yl-α-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 61 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:271040 CAPLUS
DOCUMENT NUMBER: 130:347408
TITLE: Imidazole[1,2-a]pyridine derivatives as inhibitors for

STAT6 6 transcription factor activation

INVENTOR(S): Inoue, Tadahiro; Iwai, Kiyotaka; Murata, Masashi; Nishinaka, Shigeyuki; Aoki, Mikio; Kawakami, Hajime

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11116481	A2	19990427	JP 1997-290258	19971006

PRIORITY APPLN. INFO.: JP 1997-290258 19971006
OTHER SOURCE(S): MARPAT 130:347408

AB Imidazole[1,2-a]pyridine derivs. (Markush's structure given) and their pharmaceutically acceptable salts are claimed as inhibitors for STAT6 6 transcription factor activation and IL 4 antagonists for treatment of allergic, autoimmune, parasital, viral, and bacterial diseases, tumors, host-vs. graft syndrome, systemic lupus erythematosus, and AIDS.

IT **158959-18-3P 174629-57-3P 224633-75-4P**
224633-76-5P 224633-77-6P 224633-78-7P
224633-79-8P 224633-80-1P 224633-81-2P
224633-82-3P 224633-83-4P 224633-85-6P
224633-95-8P 224633-99-2P 224634-01-9P
224634-03-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(imidazole[1,2-a]pyridine derivs. as inhibitors for STAT6 6 transcription factor activation)

RN 158959-18-3 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 174629-57-3 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-chlorophenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-75-4 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-(2-naphthalenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-76-5 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-methylphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-77-6 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-bromophenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-78-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-chloro-2-(4-fluorophenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-79-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-chloro-2-(4-chlorophenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-80-1 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-chloro-2-(3-methoxyphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-81-2 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-chloro-2-(2-naphthalenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-82-3 CAPLUS

CN Imidazo[1,2-a]pyridine, 2-[1,1'-biphenyl]-4-yl-6-methyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-83-4 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-methyl-2-(4-methylphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-85-6 CAPLUS
CN Imidazo[1,2-a]pyridine, 7-methyl-2-(4-methylphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-95-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-methylphenyl)-6-(trifluoromethyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224633-99-2 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-(trifluoromethyl)phenyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224634-01-9 CAPLUS
CN Imidazo[1,2-a]pyridine, 6-chloro-2-(4-methylphenyl)-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 224634-03-1 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[1,1'-biphenyl]-4-yl-, monohydrobromide (9CI) (CA INDEX NAME)

IT **207277-26-7P 207277-27-8P 207277-28-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-methoxyphenylpiperazine derivs. as antipsychotics)
RN 207277-26-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 207277-27-8 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 207277-28-9 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butoxy]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 67 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:268348 CAPLUS
DOCUMENT NUMBER: 128:321662
TITLE: Compositions and methods for treating bone deficit conditions
INVENTOR(S): Orme, Mark W.; Baindur, Nand; Robbins, Kirk G.; et al.
PATENT ASSIGNEE(S): Zymogenetics, Inc., USA; Osteoscreen, Inc.
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817267	A1	19980430	WO 1997-US18864	19971023
W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, US, US, US, US, US, US, US, US, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5990169	A	19991123	US 1997-806771	19970226
US 6153631	A	20001128	US 1997-806768	19970226
US 6251901	B1	20010626	US 1997-806769	19970226
US 5919808	A	19990706	US 1997-808743	19970228
US 5922753	A	19990713	US 1997-808742	19970228
US 5948776	A	19990907	US 1997-808739	19970228
US 5994358	A	19991130	US 1997-808744	19970228
US 6342514	B1	20020129	US 1997-808741	19970228
US 5965573	A	19991012	US 1997-812141	19970306
AU 9749889	A1	19980515	AU 1997-49889	19971023
EP 973513	A1	20000126	EP 1997-912787	19971023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001510450	T2	20010731	JP 1998-519529	19971023
US 6649631	B1	20031118	US 1999-297188	19991119

PRIORITY APPLN. INFO.:	US 1996-735870	A2	19961023
	US 1996-735873	A2	19961023
	US 1996-735874	A2	19961023
	US 1996-735876	A2	19961023
	US 1996-735881	A2	19961023
	US 1996-736220	A2	19961023
	US 1996-736221	A2	19961023
	US 1996-736222	A2	19961023
	US 1996-736228	A2	19961023
	US 1996-736318	A2	19961023
	US 1996-736319	A2	19961023
	WO 1997-US18864	W	19971023

OTHER SOURCE(S): MARPAT 128:321662
GI



II

AB Compds. containing 2 covalently linked aromatic systems, i.e. Ar1LAr2 [I; Ar1, Ar2 = (un)substituted Ph, naphthyl, or 5- or 6-membered aromatic heterocyclyl; L = linker (atoms or covalent bond per se) so as to space the aromatic systems at a distance of 1.5-15 Å] are effective in treating conditions associated with bone deficits. The compds. can be administered to vertebrate subjects alone or in combination with addnl. agents that

promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems. A variety of compds. were prepared and/or tested by high-throughput screening. For instance, title compound II was prepared by condensation of 2-chloro-5-(trifluoromethyl)pyridine with ethylenediamine in the presence of EtN(Pr-iso)2 at reflux. At 5-50 μg/kg/day in ovariectomized rats, II stimulated bone growth with volume increases of 21-71% observed In a calvarial bone growth assay, another compound I induced a 4-fold increase in width of new calvarial bone vs. controls.

IT **31562-99-9 205655-12-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(preparation and/or use of linked aromatic and heteroarom. compds. for treating
bone deficit conditions)

RN 31562-99-9 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 205655-12-5 CAPLUS
CN Phenol, 3-imidazo[1,2-a]pyridin-2-yl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 68 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:55635 CAPLUS
DOCUMENT NUMBER: 128:114954
TITLE: Preparation and formulation of thienyloxadiazole derivatives and analogs as anti-phencyclidine agents
INVENTOR(S): Kimura, Takenori; Murakami, Takeshi; Ohmori, Junya; Morita, Takuma; Tsukamoto, Shin-ichi
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800420	A1	19980108	WO 1997-JP2255	19970630

W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH,



RN 144701-75-7 CAPLUS
CN 1H-Benzimidazole, 2-butyl-6-imidazo[1,2-a]pyridin-2-yl-4-methyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 86 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:83664 CAPLUS
DOCUMENT NUMBER: 116:83664
TITLE: Preparation of 5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine derivatives as antihypertensives
INVENTOR(S): Aono, Tetsuya; Shimamoto, Norio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03206042	A2	19910909	JP 1990-833	19900106
PRIORITY APPLN. INFO.:			JP 1990-833	19900106

OTHER SOURCE(S): MARPAT 116:83664

GI



I

AB The title compds. [I; R1 = H, (un)substituted aliphatic, acyl or sulfonyl; R2 = H, (un)substituted aromatic or aliphatic] are prepared as K channel opener. Thus, 14.8 g 1,1'-carbonyldiimidazole was added to a solution of 12 g 2,6-F2C6H3CO2H in THF and thereto after stirring 15 min at room temperature 9.73 g 3-amino-ε-caprolactam was added and the mixture was stirred 5 h at room temperature to give 13.5 g 3-(2,6-difluorobenzoylamino)-ε-caprolactam which (8.96 g) was refluxed 24 h, with 8.96 g P4S10 in pyridine to give 23.8% I (R1 = H, R2 = 2,6-F2C6H3)(II). II and I [R1 = H, R2 = (Z)-4-Et2NC6H4CH:CH] (III) in vitro inhibited 8 and 100%, resp., rat aorta contraction induced by Et3NCl and BaCl2 and gave no inhibition of the one induced by 80 mM KCl. II and III at 1 mg/kg i.v. lowered 49 and 46%, resp. the blood pressure of rats. A total of 175 I were prepared

IT **138621-33-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antihypertensive)

RN 138621-33-7 CAPLUS

CN 4H-Thiazolo[5,4-b]azepine, 5,6,7,8-tetrahydro-2-imidazo[1,2-a]pyridin-2-yl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L4 ANSWER 87 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1988:570365 CAPLUS
DOCUMENT NUMBER: 109:170365
TITLE: Synthesis of (aryloxy)alkylamines. 2. Novel imidazo-fused heterocycles with calcium channel blocking and local anesthetic activity
AUTHOR(S): Sanfilippo, Pauline J.; Urbanski, Maud; Press, Jeffery B.; Dubinsky, Barry; Moore, John B., Jr.
CORPORATE SOURCE: Res. Lab., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SOURCE: Journal of Medicinal Chemistry (1988), 31(11), 2221-7
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:170365



L4 ANSWER 96 OF 96 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1975:471745 CAPLUS
DOCUMENT NUMBER: 83:71745
TITLE: Pharmacology of zolimidine [2-(p-methylsulfonylphenyl)imidazo(1,2-a)pyridine], a new nonanticholinergic gastroprotective agent. I. Protective activity against experimental neurogenic gastric ulcers and other pharmacologic properties
AUTHOR(S): Murmann, W.; Carminati, G. M.; Cattaneo, R.
CORPORATE SOURCE: Res. Dep., Selvi C. S.p.A., Milan, Italy
SOURCE: Panminerva Medica (1974), 16(10), 301-20
CODEN: PMMDAE; ISSN: 0031-0808
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Zolimidine (I) [1222-57-7] had low toxicity as well as a potent inhibitor of gastric ulcers of neurogenic origin in rats. At doses slightly higher than antiulcer doses, I exerted antiinflammatory and antipyretic actions; at yet somewhat higher doses it exerted central sedation without affecting reflex activity. Muscle relaxant and antihistaminic activities were also demonstrated in vitro. Both in vitro and in vivo the drug is totally devoid of anticholinergic activity. I appears to exert its action directly on the gastric mucus cells.
IT **1222-57-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 1222-57-7 CAPLUS
CN Imidazo[1,2-a]pyridine, 2-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:32:42 ON 08 OCT 2004)

FILE 'REGISTRY' ENTERED AT 15:32:55 ON 08 OCT 2004
L1 STRUCTURE UPLOADED
L2 18 S L1
L3 1944 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:35:02 ON 08 OCT 2004

L4 96 S L3/THU

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,O,X,Ak

Structure attributes must be viewed using STN Express query preparation.

=>

PALM INTRANET

Day : Tuesday
Date: 10/12/2004
Time: 11:58:08

Inventor Name Search Result

Your Search was:

Last Name = MUTEL
First Name = VINCENT

Application#	Patent#	Status	Date Filed	Title
10809068	Not Issued	030	03/25/2004	SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES
10438361	6803381	150	05/14/2003	CARBAMIC ACID DERIVATIVES
10407929	Not Issued	041	04/04/2003	PHENYLETHYNYL AND STYRYL DERIVATIVES OF IMIDAZOLE AND FUSED RING HETEROCYCLES
10407928	Not Issued	094	04/04/2003	SUBSTITUTED IMIDAZO [1,2-A] PYRIDINE DERIVATIVES
10397908	Not Issued	041	03/26/2003	1-SULFONYL PYRROLIDINE DERIVATIVES
10396172	Not Issued	041	03/25/2003	PHENYLETHYNYL AND STYRYL DERIVATIVES OF IMIDAZOLE AND FUSED RING HETEROCYCLES
10300449	Not Issued	080	11/20/2002	GLUTAMATE RECEPTOR ANTAGONISTS
10157338	6673795	150	05/29/2002	PYRIMIDINE, PYRAZINE AND TRIAZINE DERIVATIVES
10135150	Not Issued	161	04/29/2002	4-AMINOPYRIMIDINE DERIVATIVES
10116597	6548495	150	04/03/2002	DIHYDRO-BENZO [B] [1,4] DIAZEPIN-2-ONE DERIVATIVES
10115826	6544985	150	04/03/2002	DIHYDRO-BENZO [B] [1,4] DIAZEPIN-2-ONE DERIVATIVES
10093790	6596731	150	03/08/2002	SUBSTITUTED IMIDAZO[1,2-A] PYRIDINE DERIVATIVES
10020680	6586422	150	12/12/2001	PYRAZINE AND TRIAZINE DERIVATIVES OF 1,2,4,5-TETRAHYDRO-BENZO OR THIENO [D] AZEPINE
10008827	6596743	150	12/10/2001	CARBAMIC ACID DERIVATIVES
09996641	6706707	150	11/28/2001	PHENYLETHYNYL AND STYRYL DERIVATIVES OF IMIDAZOLE AND FUSED RING HETEROCYCLES

09902916	6369222	150	07/11/2001	NOVEL MGLUR ANTAGONISTS AND A METHOD FC THEIR SYNTHESIS
09892994	6399641	150	06/27/2001	NOVEL 2H-TETRAZOLE-AMIDE COMPOUNDS WITH THERAPEUTIC ACTIVITY AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS
09880539	6589978	150	06/13/2001	1-SULFONYL PYRROLIDINE DERIVATIVES
09687241	6509328	150	10/13/2000	GLUTAMATE RECEPTOR ANTAGONISTS
09687240	6407094	150	10/13/2000	GLUTAMATE RECEPTOR ANTAGONISTS
09669583	6548522	150	09/26/2000	METHOD FOR TREATING CONDITIONS RELATED T THE GLUTAMATE RECEPTOR USING CARBOXYLIC ACID AMIDE DERIVATIVES
09630702	6218385	150	08/01/2000	1,2,4,5-TETRAHYDRO-BENZO[D]AZEPIN DERIVATIVES
09545622	6462198	150	04/10/2000	CARBAMIC ACID DERIVATIVES
09534380	6284785	150	03/24/2000	1-ARENESULFONYL-2-ARYL-PYROLIDINE AND PYRIDINE DERIVATIVES
09385935	6107342	150	08/30/1999	2-AMINO-BICYCLO[3.1.0]HEXANE-2,6-DICARBOXYI ACID DERIVATIVES AND A PROCESS FOR THE PREPARATION THEREOF
09320307	6071929	150	05/26/1999	OCTAHYDRO PHENANTHRIDINE DERIVATES USEF AS NMDA-R RECEPTOR SUBTYPE BLOCKERS
09304624	6054588	150	05/04/1999	HETEROCYCLIC VINYL ETHERS
09304561	Not Issued	161	05/04/1999	HETEROCYCLIC VINYL ETHERS
09121737	Not Issued	161	07/23/1998	HETEROCYCLIC VINYL ETHERS
09115191	5958931	150	07/14/1998	PHENYL-SUBSTITUTED 5H-THIAZOLO[3,2-A] PYRIMIDINE DERIVATIVE GLUTAMATE RECEPTOI ANTAGONISTS
09008724	5952344	250	01/19/1998	TETRAHYDROISOQUINOLINE DERIVATIVES
08813523	5962472	150	03/07/1997	USE OF 4-PHENYL-3,6-DIHYDRO-2H-PYRIDYL DERIVATIVES
08789351	Not Issued	164	01/27/1997	TETRAHYDROISOQUINOLINE DERIVATIVES

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name
Mutel	Vincent

Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page